Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ProQR Therapeutics NV PRQR

Healthcare Biotechnology
ProQR Therapeutics N.V. is a pre-clinical stage biopharmaceutical company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. It designs its therapeutic candidates to specifically target and repair the defective messenger RNA, or Messenger Ribonucleic Acid (mRNA), that is... see more

Recent & Breaking News (NDAQ:PRQR)

ProQR Receives € 4.7 million in Innovation Credit from Dutch Government for QR-110 for LCA10

GlobeNewswire December 10, 2018

ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

GlobeNewswire December 4, 2018

ProQR to Present at the Evercore ISI HealthConX Conference

GlobeNewswire November 20, 2018

Consolidated Research: 2018 Summary Expectations for ProQR Therapeutics N.V, Biomerica, VEREIT, Apergy, Zendesk, and Arcus Biosciences — Fundamental Analysis, Key Performance Indications

GlobeNewswire November 16, 2018

ProQR Announces Financial Results for the Third Quarter of 2018

GlobeNewswire November 7, 2018

ProQR Announces Presentations at the European Oligonucleotide and Peptide Therapeutics Conference

GlobeNewswire October 31, 2018

ProQR In-licenses Worldwide Rights to Ophthalmology Drug Candidate from Ionis Pharmaceuticals

GlobeNewswire October 29, 2018

ProQR to Present at the Chardan Genetic Medicines Conference

GlobeNewswire October 2, 2018

ProQR Announces Presentations at the OTS Annual Meeting

GlobeNewswire September 24, 2018

ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares

GlobeNewswire September 11, 2018

ProQR Prices $90.6 Million Underwritten Public Offering of Ordinary Shares

GlobeNewswire September 7, 2018

ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares

GlobeNewswire September 5, 2018

ProQR Announces Positive Interim Results from Phase 1/2 Clinical Trial of QR-110 in LCA10 Patients, and Plans to Start a Phase 2/3 Pivotal Trial

GlobeNewswire September 5, 2018

ProQR to Present Interim Phase 1/2 Results for QR-110 in Leber’s Congenital Amaurosis 10 at the Symposium for Retinal Degeneration on Sept. 5th

GlobeNewswire August 15, 2018

ProQR Announces Financial Results for the Second Quarter of 2018

GlobeNewswire August 8, 2018

ProQR Announces Publication on QR-110 for Leber’s Congenital Amaurosis 10 in the Journal Molecular Therapy - Nucleic Acids

GlobeNewswire August 1, 2018

ProQR Announces Presentations on Programs in Ophthalmology at Conferences in July

GlobeNewswire July 12, 2018

ProQR Initiates Phase 1/2 Clinical Trial of QR-313 for Dystrophic Epidermolysis Bullosa

GlobeNewswire June 28, 2018

ProQR to Present at the JMP Life Sciences Conference

GlobeNewswire June 14, 2018

ProQR Receives up to $5 Million in Partnership with EB Research Partnership and EB Medical Research Foundation to Develop QR-313 for the Treatment of Dystrophic Epidermolysis Bullosa

GlobeNewswire June 12, 2018